Summary:
«Precise Bio combines engineering, biomaterials, cell technology, bioengineering, and 3D printing into a 4D bio-fabrication platform for transplantable organs and tissues. The company’s proprietary platform technology allows to fabricate tissues by ‘printing’ cells in a single-cell resolution and spatial accuracy, enabling complex organoid constructs with both structural integrity and long-term cell viability.»
«Precise Bio’s ophthalmological pipeline consists of three products, the two cornea products that are the subject of the collaboration with Carl Zeiss Meditec and a retinal implant for age-related macular degeneration, all of which demonstrated successful results in animal models. The company’s ophthalmological products address global markets exceeding $10 billion annually.»
«Bio-fabricated tissues comprised of human cells and natural materials, mimicking the anatomical structure and natural tissue components, can replace damaged or diseased tissue, substitute for donor tissue in cases where there is lack of tissue or solve unmet therapeutic needs.»
Article written by Med-Tech Innovation News.
20|07|2022
Source:
Med-Tech Innovation News